$8.31−0.05 (−0.60%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD
Arcturus Therapeutics Holdings (ARCT) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
Business engineChoppy: revenue is 60% below its peak, net margin −80.2%.
The four lines that matter · FY21–FY25
Revenue ($M)▼46.1%
82.0
FY21→FY25CAGR +60.5%/yr
Net income ($M)▲18.7%
−65.8
one-off year: see footnoteCAGR —
Free cash flow ($M)▼23.4%
−74.5
FY21→FY25CAGR —
Diluted EPS▲20.0%
−2.40
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+4.1%
26.3mn → 27.4mn diluted shares since FY21. Broadly flat, so EPS moves with net income rather than with the share count.
Capex
$230.0K
−64.5% YoY in FY25 · 0.3% of revenue.
What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)
-80¢ of every revenue dollar becomes profit.
Margin trend · direction beats level Gross Operating Net
Over this window: gross 100.0% → 100.0%. Net margin -80.2% is below the sector median.
The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | 30,514.0 | 82,031.0 | 152,310.0 | 166,799.0 | 205,999.0 | 12,359.0 | ▼46.1% | +60.5% |
Cost of revenue | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — |
Gross profit | 30,514.0 | 82,031.0 | 152,310.0 | 166,799.0 | 205,999.0 | 12,359.0 | ▼46.1% | +60.5% |
Research & development | 80,515.0 | 112,212.0 | 195,156.0 | 192,133.0 | 147,751.0 | 173,760.0 | ▼42.5% | −10.4% |
Selling, general & admin | 44,966.0 | 46,079.0 | 52,823.0 | 52,871.0 | 46,071.0 | 41,451.0 | ▼12.8% | +2.7% |
Total operating expenses | 125,481.0 | 158,291.0 | 247,979.0 | 245,004.0 | 193,822.0 | 215,211.0 | ▼36.2% | −7.4% |
Operating incomefeeds ROC rank | −94,967.0 | −76,260.0 | −95,669.0 | −78,205.0 | 12,177.0 | −202,852.0 | ▲20.3% | — |
Other income, net | 7,721.0 | 10,477.0 | 14,724.0 | 50,315.0 | −1,533.0 | −822.0 | — | — |
Pretax income | −87,246.0 | −65,783.0 | −80,945.0 | −27,890.0 | 10,644.0 | −203,674.0 | ▲18.7% | — |
Income tax | — | 0.0 | −4.0 | 1,835.0 | 1,295.0 | 0.0 | — | — |
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings | −87,242.0 | −65,783.0 | −80,941.0 | −29,725.0 | 9,349.0 | −203,674.0 | ▲18.7% | — |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | −3.10 | −2.40 | −3.00 | −1.12 | 0.35 | −7.74 | ▲20.0% | — |
Diluted shares (mn) | 28.44 | 27.39 | 27.00 | 26.63 | 27.09 | 26.32 | ▲1.4% | +1.0% |
| Margins | ||||||||
Gross margin82nd pct in Healthcare | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | ▲0.0pp | +0.0pp |
Operating margin | −311.2% | −93.0% | −62.8% | −46.9% | 5.9% | −1641.3% | ▼30.2pp | +1548.4pp |
Net margin24th pct in Healthcare | −285.9% | −80.2% | −53.1% | −17.8% | 4.5% | −1648.0% | ▼27.1pp | +1567.8pp |
† TTM = trailing four quarters through 2026-09-30.FY22 effective tax rate was 12% vs a 0% norm for this window, likely a one-time item; see the filing.
3 more years of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-03-03 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was Arcturus Therapeutics Holdings' revenue last fiscal year?
Arcturus Therapeutics Holdings reported revenue of $82.0M in fiscal 2025, down 46.1% from fiscal 2024.
What was Arcturus Therapeutics Holdings' net income?
Arcturus Therapeutics Holdings reported net income of −$65.8M in fiscal 2025, a net margin of −80.2%.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

